MX2021009727A - Anticuerpos que se unen al tejido tumoral para diagnóstico y tratamiento. - Google Patents

Anticuerpos que se unen al tejido tumoral para diagnóstico y tratamiento.

Info

Publication number
MX2021009727A
MX2021009727A MX2021009727A MX2021009727A MX2021009727A MX 2021009727 A MX2021009727 A MX 2021009727A MX 2021009727 A MX2021009727 A MX 2021009727A MX 2021009727 A MX2021009727 A MX 2021009727A MX 2021009727 A MX2021009727 A MX 2021009727A
Authority
MX
Mexico
Prior art keywords
antibodies
tumor tissue
diagnostic
therapeutic uses
bind tumor
Prior art date
Application number
MX2021009727A
Other languages
English (en)
Inventor
William H Robinson
Wayne Volkmuth
Jeff Defalco
Daniel Eric Emerling
Jessica Finn
Norman Michael Greenberg
Vera Huang
Shaun M Lippow
Fengling Liu
Bog Amy Manning-
Alexander Scholz
Tito Serafini
Yann Chong Tan
Nikhil Vad
Original Assignee
Atreca Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Atreca Inc filed Critical Atreca Inc
Publication of MX2021009727A publication Critical patent/MX2021009727A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/44—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material not provided for elsewhere, e.g. haptens, metals, DNA, RNA, amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/06—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies from serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/283—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against Fc-receptors, e.g. CD16, CD32, CD64
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6854—Immunoglobulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/32—Immunoglobulins specific features characterized by aspects of specificity or valency specific for a neo-epitope on a complex, e.g. antibody-antigen or ligand-receptor
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Biomedical Technology (AREA)
  • Cell Biology (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Endocrinology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Biotechnology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

En el presente documento se proporcionan anticuerpos que se unen al tejido tumoral a través de una interacción de unión con un complejo extracelular de ARN-proteína. Dichos anticuerpos se utilizan en métodos para inducir una respuesta inmunitaria y métodos para inhibir el crecimiento de células tumorales. Además, se proporcionan métodos para producir tales anticuerpos.
MX2021009727A 2019-02-15 2020-02-14 Anticuerpos que se unen al tejido tumoral para diagnóstico y tratamiento. MX2021009727A (es)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201962806310P 2019-02-15 2019-02-15
US201962806285P 2019-02-15 2019-02-15
US201962843298P 2019-05-03 2019-05-03
US201962843751P 2019-05-06 2019-05-06
US201962852830P 2019-05-24 2019-05-24
US201962927501P 2019-10-29 2019-10-29
PCT/US2020/018350 WO2020168231A2 (en) 2019-02-15 2020-02-14 Antibodies that bind tumor tissue for diagnosis and therapy

Publications (1)

Publication Number Publication Date
MX2021009727A true MX2021009727A (es) 2021-11-12

Family

ID=69845562

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2021009727A MX2021009727A (es) 2019-02-15 2020-02-14 Anticuerpos que se unen al tejido tumoral para diagnóstico y tratamiento.

Country Status (19)

Country Link
US (2) US11472885B2 (es)
EP (2) EP4253422A3 (es)
JP (1) JP7365421B2 (es)
KR (1) KR102592844B1 (es)
CN (1) CN114040774A (es)
AU (1) AU2020223356B2 (es)
BR (1) BR112021016121A2 (es)
CA (1) CA3129637A1 (es)
DK (1) DK3806895T3 (es)
ES (1) ES2956413T3 (es)
FI (1) FI3806895T3 (es)
IL (1) IL285541A (es)
MX (1) MX2021009727A (es)
NZ (1) NZ782502A (es)
PL (1) PL3806895T3 (es)
PT (1) PT3806895T (es)
SG (1) SG11202108645YA (es)
TW (1) TW202045542A (es)
WO (1) WO2020168231A2 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2023545012A (ja) * 2020-10-05 2023-10-26 フリーノム ホールディングス，インク． 結腸細胞増殖性障害を早期発見するためのマーカー
WO2022081843A1 (en) * 2020-10-15 2022-04-21 Atreca, Inc. Antibody scaffold structure
CN113447648B (zh) * 2021-07-01 2022-04-19 浙江大学 检测抗富含丝氨酸/精氨酸剪接因子9-IgG抗体的试剂盒
WO2023010057A1 (en) * 2021-07-28 2023-02-02 Atreca, Inc. Atrc-101 target expression assay

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2233878C2 (ru) * 1997-01-21 2004-08-10 Дзе Дженерал Хоспитал Корпорейшн Способ отбора желательного белка и нуклеиновой кислоты, средства для его осуществления
US6261804B1 (en) * 1997-01-21 2001-07-17 The General Hospital Corporation Selection of proteins using RNA-protein fusions
WO2005040810A1 (en) * 2003-10-15 2005-05-06 Roche Diagnostics Gmbh Use of protein hnrnp-k as a marker for breast cancer
EP2927322A1 (en) * 2004-06-10 2015-10-07 Viventia Bio Inc. Tumor specific antibody
CA2860228A1 (en) * 2011-12-23 2013-06-27 Egen, Inc. Compositions and methods for the delivery of biologically active rnas
US20150011405A1 (en) * 2013-07-03 2015-01-08 Atreca, Inc. Use of Nanoexpression to Interrogate Antigen Repertoires
WO2017010568A1 (ja) * 2015-07-16 2017-01-19 国立大学法人京都大学 Ｒｎａ－タンパク質複合体とその使用

Also Published As

Publication number Publication date
ES2956413T3 (es) 2023-12-20
NZ782502A (en) 2023-10-27
BR112021016121A2 (pt) 2022-01-04
EP4253422A3 (en) 2023-12-06
EP3806895B1 (en) 2023-06-21
US20200325242A1 (en) 2020-10-15
PT3806895T (pt) 2023-07-27
EP3806895A2 (en) 2021-04-21
WO2020168231A2 (en) 2020-08-20
EP4253422A2 (en) 2023-10-04
SG11202108645YA (en) 2021-09-29
PL3806895T3 (pl) 2024-02-19
AU2020223356B2 (en) 2023-12-07
KR20210139258A (ko) 2021-11-22
WO2020168231A3 (en) 2020-09-24
US11472885B2 (en) 2022-10-18
IL285541A (en) 2021-09-30
CA3129637A1 (en) 2020-08-20
JP2022520479A (ja) 2022-03-30
DK3806895T3 (da) 2023-07-24
KR102592844B1 (ko) 2023-10-20
AU2020223356A1 (en) 2021-10-07
FI3806895T3 (fi) 2023-09-13
JP7365421B2 (ja) 2023-10-19
TW202045542A (zh) 2020-12-16
US20230140035A1 (en) 2023-05-04
CN114040774A (zh) 2022-02-11

Similar Documents

Publication Publication Date Title
MX2021009727A (es) Anticuerpos que se unen al tejido tumoral para diagnóstico y tratamiento.
PH12019500545A1 (en) Cd3 binding antibodies
MX2018016404A (es) Anticuerpos de union a cd3.
JOP20200237A1 (ar) الأجسام المضادة لمضاد cd3 وجزيئات ربط الأنتيجين ثنائية التحديد التي تربط cd3 وcd20 واستخداماتها
MY194642A (en) Antibodies binding to cd3
MX2021013336A (es) Anticuerpos y receptores de antigeno quimericos especificos para cd19.
MX2020006715A (es) Anticuerpos especificos del heterodimero de cd3-delta/epsilon.
PH12020551160A1 (en) Chimeric antigen receptors targeting cd70
MX2019010583A (es) Anticuerpos contra ligando 1 de muerte programada.
NZ756678A (en) Anti-lag-3 antibodies and uses thereof
MX2019009468A (es) Proteínas de unión multiespecíficas para la activación de células asesinas naturales y usos terapéuticos de las mismas para tratar cáncer.
WO2018217940A3 (en) Pd-1/lag3 bi-specific antibodies, compositions thereof, and methods of making and using the same
PH12021550690A1 (en) Anti-hla-g antibodies, compositions comprising anti-hla-g antibodies and methods of using anti-hla-g antibodies
MX2019015349A (es) Anticuerpos biespecificos para receptor 1 huerfano tipo receptor de tirosina cinasa (ror1) y grupo de diferenciacion 3 (cd3).
MX349662B (es) Anticuerpos de antigenos antitumorales y metodos de uso.
SG10201909308XA (en) Bispecific antibody constructs for cdh3 and cd3
MX2017005977A (es) Anticuerpos biespecificos y metodos de uso en oftalmologia.
MX2020010913A (es) Anticuerpos anti-cd27 y anti-pd-l1 y constructos biespecíficos.
MY160590A (en) Cd127 binding proteins
PH12019502302A1 (en) Anti-pd-l1 antibody and use thereof
CR20200463A (es) Anticuerpos
PH12018500131A1 (en) Il22 immunoconjugates
MX2015008117A (es) Anticuerpos anti-h7cr.
WO2017177217A3 (en) Chimeric receptors and uses thereof in immune therapy
PH12017500018A1 (en) Myo-inositol and probiotics, and their use